A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects

Vaccine

Volumn 28, Issue 9, 2010, Pages 2076-2079

  Cate, Thomas R ^a   Rayford, Yolanda ^a   Niño, Diane ^a   Winokur, Patricia ^b   Brady, Rebecca ^c   Belshe, Robert ^d   Chen, Wilbur ^e   Atmar, Robert L ^a   Couch, Robert B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Influenza vaccine; Neuraminidase

Indexed keywords

ANTIGEN; ENZYME ANTIBODY; INFLUENZA VACCINE; LECTIN; NEURAMINIDASE ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; PRIORITY JOURNAL; PROTECTION; PROTEIN DETERMINATION; VACCINATION;

AGED; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; VACCINES, INACTIVATED;

EID: 77149133721     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.041     Document Type: Article

References (20)

1. Couch R.B., Kasel J.A., Six H.R., Cate T.R., and Zahradnik J.M. Immunological reactions and resistance to infection with influenza virus. In: Stuart-Harris C., and Potter C. (Eds). The molecular virology and epidemiology of influenza 1983. London (1984), Academic Press 119-152
2. Couch R.B. An overview of serum antibody responses to influenza virus antigens. In: Brown F., Haaheim L.R., Wood J.M., and Schild G.C. (Eds). Developments in biologicals: laboratory correlates of immunity to influenza 115 (2003), Karger 25-30
3. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 26S (2008) D5-D9
4. Kilbourne E.D. Influenza (1987), Plenum Publishing Corporation, New York
5. Palese P., Tobita K., Ueda M., and Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61 (1974) 397-410
6. Murphy B.R., Kasel J.A., and Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 286 (1972) 1329-1332
7. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., and Kilbourne E.D. Induction of partial immunity to influenza using a neuraminidase-specific vaccine. J Infect Dis 129 4 (1974) 411-420
8. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 353 (2005) 1363-1373
9. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25 (2007) 7656-7663
10. Lambré C.R., Terzidis H., Greffard A., and Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtiter plates coated with natural substrates. J Immunol Methods 135 (1990) 49-57
11. Kilbourne E.D., Laver W.G., Schulman J.L., and Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. I. In vitro effects. J Virol 2 (1968) 281-288
12. Schulman J.L., Khakpour M., and Kilbourne E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2 (1968) 778-786
13. Mozdzanowska K., Maiese K., Furchner M., and Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titre but fails to clear the infection. Virology 254 (1999) 138-146
14. Takahashi Y., Hasegawa H., Hara Y., Ato M., Ninomiya A., Takagi H., et al. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 199 (2009) 1629-1637
15. Johansson B.E., Bucher D., and Kilbourne E. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 63 (1989) 1239-1246
16. Ogra P.L., Chow T., Beutner K.R., Rubi E., Strussenberg J., DeMello S., et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 135 (1977) 499-506
17. Kilbourne E.D., Couch R.B., Kasel J.A., Keitel W.A., Cate T.R., Quarles J.M., et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13 (1995) 1799-1803
18. Powers D., Kilbourne E., and Johansson B. Neuraminidase-specific antibody responses to inactivated influenza vaccine in young and elderly adults. Clin Diagn Lab Immunol 3 (1996) 511-516
19. Muhamed G., Greenbaum E., and Zakay-Rones Z. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Isr Med Assoc J 8 (2006) 155-158
20. Kilbourne E.D., Johansson B.E., and Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci U S A 87 (1990) 786-790